Vor Biopharma Inc. is the subject of an amended Schedule 13G filing by several Frazier Life Sciences-affiliated funds and entities, which together act as institutional investors rather than as individuals. The main holder, Frazier Life Sciences Public Fund, L.P., reports beneficial ownership of 2,258,001 shares of Vor Biopharma common stock, representing 4.2% of the class, with no sole voting or dispositive power and only shared powers through its control structure.
Additional Frazier vehicles report smaller positions: Frazier Life Sciences XI, L.P. holds 21,114 shares (0.0% of the class) and Frazier Life Sciences XII, L.P. holds 264,824 shares (0.5% of the class), each with shared voting and dispositive power only. All percentage interests are calculated based on 54,185,877 shares outstanding as of May 7, 2026. The filers state that no individual committee members are attributed beneficial ownership and that the filing does not admit membership in any group.
Positive
None.
Negative
None.
Key Figures
Shares outstanding:54,185,877 sharesFLSPF shares owned:2,258,001 sharesFLSPF percent of class:4.2%+4 more
7 metrics
Shares outstanding54,185,877 sharesCommon Stock outstanding as of May 7, 2026, per Form 10-Q
FLSPF shares owned2,258,001 sharesCommon Stock directly held by Frazier Life Sciences Public Fund, L.P.
FLSPF percent of class4.2%Percent of Vor Biopharma common stock class held by FLSPF
FLS XI shares owned21,114 sharesCommon Stock directly held by Frazier Life Sciences XI, L.P.
FLS XI percent of class0.0%Percent of Vor Biopharma common stock class held by FLS XI
FLS XII shares owned264,824 sharesCommon Stock directly held by Frazier Life Sciences XII, L.P.
FLS XII percent of class0.5%Percent of Vor Biopharma common stock class held by FLS XII
"shall not be construed as an admission that any Reporting Person is, for the purposes of Section 13(d)... the beneficial owner"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
shared voting powerregulatory
"6 | Shared Voting Power 2,258,001.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerregulatory
"8 | Shared Dispositive Power 2,258,001.00"
Schedule 13Gregulatory
"the filing of this shall not be construed as an admission that any Reporting Person is, for the purposes of Section 13(d)..."
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
general partnerfinancial
"FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C."
A general partner is the person or firm that runs an investment partnership and legally represents it — they make the day-to-day decisions, choose which assets to buy or sell, and are responsible for the partnership’s obligations. Investors care because the general partner’s judgment, risk-taking and fee and profit-sharing arrangements determine both the potential returns and the level of exposure to losses; think of the GP as the ship’s captain whose skill and honesty shape the voyage’s outcome.
FAQ
What stake in Vor Biopharma (VOR) does Frazier Life Sciences Public Fund report?
Frazier Life Sciences Public Fund, L.P. reports beneficial ownership of 2,258,001 shares of Vor Biopharma common stock, representing 4.2% of the class, with only shared voting and dispositive power through its control entities.
How many Vor Biopharma (VOR) shares are outstanding for this 13G/A calculation?
All ownership percentages are calculated using 54,185,877 shares of Vor Biopharma common stock outstanding as of May 7, 2026, as disclosed in the company’s Form 10-Q filed on May 13, 2026.
Do the Frazier Life Sciences funds report owning 5% or less of Vor Biopharma (VOR)?
Yes. The reporting persons state “Ownership of 5 percent or less of a class,” and the listed stakes, including 4.2% and 0.5%, are each below the 5% threshold for Vor Biopharma common stock.
Which Frazier Life Sciences entities are included in this Vor Biopharma (VOR) Schedule 13G/A?
Reporting persons include Frazier Life Sciences Public Fund, L.P., Frazier Life Sciences XI, L.P., Frazier Life Sciences XII, L.P., and their related FHMLSP and FHMLS general-partner entities, all organized in Delaware.
Do individual Frazier committee members have beneficial ownership of Vor Biopharma (VOR) shares?
No. The filing explains that each FHMLSP and FHMLS general partner is managed by an investment committee, and no committee members are attributed beneficial ownership of the Vor Biopharma shares held by the funds.
What type of power over Vor Biopharma (VOR) shares do the Frazier entities report?
The reporting entities disclose no sole voting or dispositive power. They report only shared voting and shared dispositive power over their respective Vor Biopharma share positions through their partnership and LLC structures.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
VOR BIOPHARMA INC.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
929033207
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
929033207
1
Names of Reporting Persons
Frazier Life Sciences Public Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,258,001.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,258,001.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,258,001.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.2 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
929033207
1
Names of Reporting Persons
FHMLSP, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,258,001.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,258,001.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,258,001.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.2 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
929033207
1
Names of Reporting Persons
FHMLSP, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,258,001.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,258,001.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,258,001.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.2 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
929033207
1
Names of Reporting Persons
Frazier Life Sciences XI, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
21,114.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
21,114.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
21,114.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
929033207
1
Names of Reporting Persons
FHMLS XI, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
21,114.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
21,114.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
21,114.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
929033207
1
Names of Reporting Persons
FHMLS XI, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
21,114.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
21,114.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
21,114.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
929033207
1
Names of Reporting Persons
Frazier Life Sciences XII, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
264,824.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
264,824.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
264,824.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.5 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
929033207
1
Names of Reporting Persons
FHMLS XII, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
264,824.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
264,824.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
264,824.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.5 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
929033207
1
Names of Reporting Persons
FHMLS XII, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
264,824.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
264,824.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
264,824.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.5 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 54,185,877 shares of Common Stock outstanding on May 7, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
VOR BIOPHARMA INC.
(b)
Address of issuer's principal executive offices:
500 Boylston Street, Suite 1350, Boston, MA, 02116.
Item 2.
(a)
Name of person filing:
The entities and persons filing this statement (collectively, the "Reporting Persons") are:
Frazier Life Sciences Public Fund, L.P. ("FLSPF")
FHMLSP, L.P.
FHMLSP, L.L.C.
Frazier Life Sciences XI, L.P. ("FLS XI")
FHMLS XI, L.P.
FHMLS XI, L.L.C.
Frazier Life Sciences XII, L.P. ("FLS XII")
FHMLS XII, L.P.
FHMLS XII, L.L.C.
(b)
Address or principal business office or, if none, residence:
The address of the principal place of business for each of the Reporting Persons is:
c/o Frazier Life Sciences Management, L.P.
1001 Page Mill Rd, Building 4, Suite 200B
Palo Alto, CA 94304
(c)
Citizenship:
The information contained in row 4 of each Reporting Person's cover page to this Schedule 13G/A is incorporated by reference.
(d)
Title of class of securities:
Common Stock, $0.0001 par value per share
(e)
CUSIP No.:
929033207
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information contained in row 9 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.
FLSPF directly holds 2,258,001 shares of Common Stock. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF.
FLS XI directly holds 21,114 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI.
FLS XII directly holds 264,824 shares of Common Stock. FHMLS XII, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII.
Except as specifically stated herein, the filing of this Schedule 13G shall not be construed as an admission that any Reporting Person is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Schedule 13G or a member of a "group" with any other person.
(b)
Percent of class:
The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.
(ii) Shared power to vote or to direct the vote:
The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Frazier Life Sciences Public Fund, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:
08/14/2026
FHMLSP, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:
08/14/2026
FHMLSP, L.L.C.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLSP, L.L.C.
Date:
08/14/2026
Frazier Life Sciences XI, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:
08/14/2026
FHMLS XI, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:
08/14/2026
FHMLS XI, L.L.C.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XI, L.L.C.
Date:
08/14/2026
Frazier Life Sciences XII, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.
Date:
08/14/2026
FHMLS XII, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.
Date:
08/14/2026
FHMLS XII, L.L.C.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XII, L.L.C.
Date:
08/14/2026
Exhibit Information
Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to Schedule 13G filed on December 19, 2025)
